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Background. Aggressive lipid lowering with high doses of statins increases the risk of statin-induced myopathy. However, the
cellular mechanisms leading to muscle damage are not known and sensitive biomarkers are needed to identify patients at risk
of developing statin-induced serious side effects. Methodology. We performed bioinformatics analysis of whole genome
expression profiling of muscle specimens and UPLC/MS based lipidomics analyses of plasma samples obtained in an earlier
randomized trial from patients either on high dose simvastatin (80 mg), atorvastatin (40 mg), or placebo. Principal Findings.
High dose simvastatin treatment resulted in 111 differentially expressed genes (1.5-fold change and p-value,0.05), while
expression of only one and five genes was altered in the placebo and atorvastatin groups, respectively. The Gene Set
Enrichment Analysis identified several affected pathways (23 gene lists with False Discovery Rate q-value,0.1) in muscle
following high dose simvastatin, including eicosanoid synthesis and Phospholipase C pathways. Using lipidomic analysis we
identified previously uncharacterized drug-specific changes in the plasma lipid profile despite similar statin-induced changes
in plasma LDL-cholesterol. We also found that the plasma lipidomic changes following simvastatin treatment correlate with the
muscle expression of the arachidonate 5-lipoxygenase-activating protein. Conclusions. High dose simvastatin affects multiple
metabolic and signaling pathways in skeletal muscle, including the pro-inflammatory pathways. Thus, our results demonstrate
that clinically used high statin dosages may lead to unexpected metabolic effects in non-hepatic tissues. The lipidomic profiles
may serve as highly sensitive biomarkers of statin-induced metabolic alterations in muscle and may thus allow us to identify
patients who should be treated with a lower dose to prevent a possible toxicity.
Citation: Laaksonen R, Katajamaa M, Pa ¨iva ¨ H, Sysi-Aho M, Saarinen L, et al (2006) A Systems Biology Strategy Reveals Biological Pathways and Plasma
Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle. PLoS ONE 1(1): e97. doi:10.1371/journal.pone.0000097
INTRODUCTION
Large-scale clinical trials have shown that statins are effective and
safe cholesterol lowering drugs [1–3]. Recently more patients have
been titrated to higher doses of statins in order to reach the new
goals of LDL-cholesterol lowering and achieve even greater
reductions of atherosclerotic complications. However, aggressive
treatment with high dosages increases the risk of statin-induced
myopathy [4]. Elucidation of myopathy mechanisms and identi-
fication of patients likely not to tolerate the treatment is therefore
of great clinical interest. In addition, comparison of different statin
drugs used for aggressive treatment is essential. The currently used
statins do have clear differences for instance in their pharmaco-
kinetic properties [5], therefore it is likely that some of the statins
at high dosages are more prone to have unexpected and unwanted
effects in non-hepatic tissues.
We do know that some diseases such as hypothyroidism, liver
dysfunction and diabetes increase the risk of muscle complications
due to statin treatment [6]. Furthermore, exercise, alcohol,
infections or underlying metabolic diseases seems to exacerbate
this risk [7]. Under these circumstances development of myopathy
may be exacerbated by interactions with statins [8]. Mukhtar and
Reckless listed four potential myopathy mechanisms in their recent
review: Depletion of intracellular cholesterol leading to calcium
influx; inhibited protein synthesis, signal transduction and
metabolism due to decreased mevalonate acid and its metabolite
concentrations; reduced ubiquinone (coenzyme Q10) concentra-
tions; and enhanced apoptosis [8]. Muscle biopsies obtained from
patients with statin-induced myopathy without creatine kinase
(CK) elevations have shown evidence of mitochondrial dysfunc-
tion, including abnormally increased lipid stores in muscles [9].
We observed decreased mitochondrial function in patients on high
dose simvastatin treatment, with no signs of myopathy [10]. Later,
we confirmed that high dose (80 mg) simvastatin affects muscle
mitochondria by assessing a significant decrease in the muscle
mitochondrial DNA (mtDNA) content during treatment (Schink et
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effects and defective mitochondrial metabolism may already be
involved during the early development of statin-induced myopathy
when the currently used plasma CK measurements are not
sensitive enough to identify these patients at risk of developing
muscle damage.
Given the existing gap in knowledge and understanding of
statin-induced muscle damage, we embarked in a systems biology
approach aiming to gain insight into the mechanism and potential
biomarkers of myopathy in the clinical setting. Of particular
relevance is to gain new knowledge of signaling and metabolic
pathways in muscle involved in myopathy and early molecular
markers applicable in clinical setting. To address both objectives,
gene expression profiling of muscle tissue is an obvious strategy of
choice. As changes in plasma lipid composition are of particular
interest in the study of statins, plasma lipidomics is one possible
option to address the latter. Recent advances in liquid chroma-
tography and mass spectrometry have empowered us with ability
to reliably measure hundreds of lipid molecular species from
biological samples in parallel [11,12].
In this paper we report the study of muscle gene expression
profiles in combination with plasma lipidome analysis before and
during high dose statin treatment. The specimens were from
patients who participated in our earlier controlled and random-
ized study comparing placebo and high dosages of atorvastatin
and simvastatin [10]. The simvastatin treated patients were
particularly unique and suitable for sensitive early marker
discovery due to changes in their mitochondrial function, mtDNA
and ubiquinone concentration in muscle. The systems biology
approach allowed us to compare two widely used statins in terms
of their effects on muscle gene expression and plasma lipidome.
In addition, we were able to illuminate relevant biological
pathways and to identify biomarker candidates related to
unwanted and potentially toxic statin-induced changes in muscle
metabolism.
METHODS
Patients
Plasma samples from 37 subjects of an earlier study [10], focusing
on the effect of high dose statin treatment on skeletal muscle
metabolism, were used for plasma lipidome analysis; placebo
(N=11), simvastatin (N=13), and atorvastatin (N=14). The
subjects aged between 45 and 69 years and their average serum
total cholesterol concentration was 5.860.9 mmol/L and serum
triglycerides below 4.5 mmol/L. Muscle specimens from eighteen
age matched men being treated either with atorvastatin (n=6),
simvastatin (n=6) or placebo (n=6) were selected for genome
wide expression analysis. Clinical parameters are available as
Supporting Information Dataset S1 and Table S1.
The study patients had never been treated with statins before.
They were instructed to adhere to their normal diet during the
study. Patients with familial hypercholesterolemia and patients
with serum total cholesterol.7.0 mmol/L in the initial screening
were excluded. Other exclusion criteria were: use of concurrent
lipid altering medication or antioxidant vitamins, renal or hepatic
dysfunction, and use of medication known to affect metabolism of
atorvastatin or simvastatin. The study protocol was accepted by
the Ethics Committee of the Tampere University Hospital and
written informed consents were obtained from all participants.
Design
The original study was a randomized, double blind and placebo-
controlled trial with three treatment groups: placebo, atorvastatin
40 mg/day, and simvastatin 80 mg/day. Placebo was simvastatin-
matched, and to ensure also blinding of atorvastatin, all study
drugs were supplied in sealed, identical, numbered containers. The
duration of the follow-up was eight weeks. Muscle biopsies were
obtained at baseline and at the end of the treatment period.
Biopsies were taken from the lateral portion of the quadriceps
femoris muscle in local anesthesia at about the mid-point between
the greater trochanter and the knee joint with a biopsy needle
(Tru-Cut, Baxter, McGaw Park, Ill., USA). The muscle specimens
were frozen within 1–2 seconds in liquid nitrogen and stored at
280uC until analyzed. The blood sampling was performed in the
Department of Clinical Chemistry, Tampere University Hospital
by an experienced laboratory technician. Venous blood was drawn
from the antecubital vein in sitting position after a twelve-hour fast
and after 15 minute rest just before blood sampling. The blood
was drawn into tubes containing EDTA, and plasma was
separated after cooling by centrifugation at 2000 rpm for
10 minutes. The samples were stored at 270u until analyzed.
Investigators performing the gene expression and lipidomics
analyses were blinded until the analyses were done.
Gene expression analyses
Microarray experiments were performed using SentrixH Human-6
Expression BeadChips, analyzing over 46 000 known genes, gene
candidates and splice variants (Illumina, San Diego, CA, USA)
according to given instructions. The biopsy samples were
homogenized using Ultra-Turrax (IKA Turrax T8/S8N-5G,
IKA-Werke, Staufen, Germany). The total RNA was extracted
using TRIzol (#15596-018, Invitrogen Corporation, Carlsbad,
CA), DNase treatment and a second RNA purification by Qiagen
kits (#74106, and, #79254, Qiagen GmbH, Hilden, Germany),
all by given instructions.
A 200 ng aliquote of total RNA from each sample were
amplified to cDNA using Ambion’s Illumina RNA Amplification
kit following the instructions (cat no I1755, Ambion, Inc., Austin,
TX, USA). In vitro transcripiton (IVT) reaction of cDNA to
cRNA was performed overnight (14h) including biotin-11-dUTP
(PerkinElmer, cat no PC 3435-0402-Biotin-11-dUTP, .95%,
NEL539001EA, PerkinElmer Life And Analytical Sciences, Inc.,
Boston, MA, USA) for labelling the cRNA product. Both before
and after the amplifications the RNA/cRNA concentrations were
checked with Nanodrop ND-1000 spectrophotometer (Nanodrop
Technologies, Wilmington, DE, USA) and RNA/cRNA quality
was controlled by BioRad’s Experion Automated Electrophoresis
System and RNA StdSens Analysis Kit (BioRad Laboratories,
Inc., Hercules, CA, USA).
1500 ng of each sample cRNA was hybridized to Illumina’s
SentrixH Human-6 Expression BeadChip arrays (Illumina, Inc.,
San Diego, CA, USA) at 55uC overnight (18 h) following the
Illumina Whole-Genome Gene Expression Protocol for BeadSta-
tion (Doc. # 11176837 Rev. F, Illumina Inc.). Hybridized
biotinylated cRNA was detected with 1 mg/ml Cyanine3-
streptavidine (Amersham Biosciences #146065). BeadChips were
scanned with Illumina BeadArray Reader.
Raw intensity data obtained from the Illumina
TM platform were
normalized with Inforsense KDE version 2.0.4 (Inforsense,
London, UK) using quantile normalization method. The same
software was also used for single-gene analyses including fold-
change calculations and filtering the probes. The differences
within the treatment group before and after the intervention were
analyzed using the t-test statistic, with p-values calculated using
5000 permutations.
Pathway analysis of the expression data was performed using
the Gene Set Enrichment Analysis (GSEA) implemented in
Statin-Affected Pathways
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duplicates in the analysis, probes representing the same gene
symbol in Illumina
TM data were replaced with their average
intensity before applying the GSEA. Gene sets for GSEA were
taken from Database C2 of MSigDB version 1.0 of March 2005
[13]. Parameters used for the GSEA analysis are provided in
Supporting Information Text S2. Gene expression data is
available at Array Express web site (http://www.ebi.ac.uk/
aerep/login; accession number E-TABM-116).
RT-PCR analysis
The microarray expression results recorded in the simvastatin
group (n=5, for one case there was not enough muscle RNA for
PCR) were verified by Real-Time Quantitative TaqMan PCR.
Previously purified cRNA was used as starting material for cDNA
synthesis. A 1000 ng–18 ml aliquote of cRNA was mixed with 1 ml
Promega Random Primer (C1181, Promega U.S., Madison, WI,
USA) and incubated in +70uC for 10 min. The following reagents
were added leading to 25 ml total reaction volume: 1 mlo f1 0mM
dNTP blend (F09892, Applied Biosystems, Foster City, CA, USA),
1 ml of Promega M-MLV Reverse Transcriptase 200 U/ml
(M3682) and 4 ml of M-MLV RT 56 reaction buffer. Finally
the incubations were performed in the following order: 10 min in
RT, 50 min in 45uC, and, 10 min in 70uC.
10 ml volume was used for PCR reaction, consisting of 2 ml
aliquote of 1:10 diluted cDNA sample, and, Abgene ABsolute 26
QPCR ROX mix (AB-1139, Abgene, Epsom, UK). The primer
concentrations were 300 nM, probe concentrations for Universal
Probe Library (Exiqon, Vedbæk, Denmark) probes 100 nM and
for ordinary long probes 200 nM. Finally the PCR reactions were
performed in rtPCR system (ABI Prism 7700 Sequence Detection
System, Applied Biosystems) having the following PCR procedure:
95uC for 15 min, and 40 cycles of 95uC for 15 s and 60uC for
1 min. The primer and probe sequences are available upon
request.
Lipidomics analysis of plasma
An aliquot (10 ml) of an internal standard mixture containing 11
lipid classes, and 0.05 M sodium chloride (10 ml) was added to
plasma samples (10 ml) and the lipids were extracted with
chloroform/methanol (2:1, 100 ml). After vortexing (2 min),
standing (1 hour) and centrifugation (10000 RPM, 3 min) the
lower layer was separated and a standard mixture containing 3
labeled standard lipids was added (10 ml) to the extracts. The
sample order for LC/MS analysis was determined by randomi-
zation.
Lipid extracts were analysed on a Waters Q-Tof Premier mass
spectrometer combined with an Acquity Ultra Performance LC
TM
(UPLC). The column, which was kept at 50uC, was an Acquity
UPLC
TM BEH C18 10650 mm with 1.7 mm particles. The
binary solvent system included A. water (1% 1 M NH4Ac, 0.1%
HCOOH) and B. LC/MS grade (Rathburn) acetonitrile/isopro-
panol (5 2, 1% 1 M NH4Ac, 0.1% HCOOH). The gradient
started from 65% A/35% B, reached 100% B in 6 min and
remained there for the next 7 min. The total run time including
a 5 min re-equilibration step was 18 min. The flow rate was
0.200 ml/min and the injected amount 0.75 ml. The temperature
of the sample organizer was set at 10uC.
The lipid profiling was carried out on Waters Q-Tof Premier
mass spectrometer using ESI+ mode. The data was collected at
mass range of m/z 300–1200 with a scan duration of 0.2 sec. The
source temperature was set at 120uC and nitrogen was used as
desolvation gas (800 L/h) at 250uC. The voltages of the sampling
cone and capillary were 39 V and 3.2 kV, respectively. Reserpine
(50 mg/L) was used as the lock spray reference compound (5 ml/
min; 10 sec scan frequency).
Data was processed using MZmine software version 0.60 [14].
Lipids were identified using internal spectral library. The
normalization was performed using multiple internal standards
as described in the Supporting Information Text S1. Only the
identified lipid molecular species were included in further data
analyses.
The Supporting Information Text S1, Figures S6–23 and
Tables S8–11 also include general lipidomics platform character-
istics such as internal and external standards used, calibration
curves, dynamic ranges, recovery, variability, identification
and quality control workflow, as well as illustrative spectra (MS
and MS/MS) demonstrating how the specific species can be
identified.
Lipid nomenclature
Lipids from the lipidomic analysis were named according to Lipid
Maps (http://www.lipidmaps.org) [15]. For example, lysopho-
sphatidylcholine with 16:0 fatty acid chain was named as
monoacyl-glycerophosphocholine GPCho(16:0/0:0). In case the
fatty acid composition was not determined, total number of
carbons and double bonds was marked. For example, a phospha-
tidylcholine species GPCho(16:0/20:4) is represented as
GPCho(36:4). However, GPCho(36:4) could also represent other
molecular species, for example GPCho(20:4/16:0) or
GPCho(18:2/18:2). Such mass isomers may be separated
chromatographically, as shown in Supporting Information Figure
S20A for two lysophosphatidylcholine species GPCho(17:0/0:0)
and GPCho(0:0/17:0).
Chemometric modeling and statistical analysis of
lipidomics data
Partial least squares discriminant analysis (PLS/DA) [16,17] was
utilized as a supervised modeling method using SIMPLS algorithm
to calculate the model [18]. As the total number of samples was
insufficient for independent validation, no hold-out dataset was
utilized for cross-validation. Instead, Venetian blinds cross-
validation method [19] and Q
2 scores were used to optimize the
model. Top loadings for latent variables associated with drug
specific effects were reported. The VIP (variable importance in the
projection) values [20] were calculated to identify the most
important molecular species for the clustering of specific groups.
Multivariate analyses were performed using Matlab version 7.2
(Mathworks, Inc.) and the PLS Toolbox version 3.5 Matlab
package (Eigenvector Research, Inc.).
The regression of lipidomics data on muscle gene expression
profiles was performed using the lasso method [21]. The lasso is
a shrinkage regression method, similar to Ridge regression [22],
which performs continuous variable selection causing some of the
regression coefficients to be exactly zero. This reduces the variance
of the regression estimates, which in the case of lipidomics data
with large number of variables would otherwise be unacceptably
high. Furthermore, the subset of lipids corresponding to non-zero
coefficients can be considered as ‘the most important’ in
explaining the muscle gene expression profiles. The lasso regression
coefficients were calculated with the Least Angle Regression
method [23] implemented in the R statistical language (package
LARS). The corrected R
2 value and the Schwartz Criterion [24]
were reported along with the measured and predicted gene
expression values.
Statin-Affected Pathways
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Gene expression analysis reveals multiple
upregulated pathways in the simvastatin group
In order to understand the pathways associated with statin response
in muscle, we performed the whole genome microarray analysis of
muscle biopsies. Microarray experiments were performed in 18 age-
matched men (6 subjects from each group) who did not have any
observed side effects such as muscle pain or CK elevations as a result
of statin treatment. However, simvastatin treated men had sub-
stantial statin-induced unwanted and potentially toxic changes in
muscle ubiquinone and mtDNA as reported earlier.
According to the used selection criteria for differentially
expressed genes (1.5-fold change and p-value,0.05), expression
of one gene was changed in the placebo group. Only modest
changes were recorded in the atorvastatin group as expression of
five genes was altered during the intervention. In the simvastatin
group, however, expression of 111 genes changed (26 down-
regulated and 85 up-regulated). Based on a hierarchical cluster
analysis 20 genes were selected for further RT-PCR control. The
following 5 genes were significantly upregulated: ALOX5AP
(+3.6-fold, p=0.041), CCL5 (+11.9-fold, p=0.011), COL3A1
(+27.1-fold, p=0.026), MYL5 (+8.0-fold, p=0.021), MYBPH
(+49.0-fold, p=0.027).
As the recorded differences in single gene expressions were
rather modest in general, we performed a Gene Set Enrichment
Analysis [13] to identify globally affected metabolic pathways. The
parameters of GSEA analysis are listed in Supporting Information
Text S2. No pathways were affected significantly in the
atorvastatin or placebo groups according to the criteria (False
Discovery Rate q-value,0.25) recommended by Subramanian et
al. [13]. However, in the simvastatin group 143 pathways were up-
regulated (q,0.25) (Supporting Information Dataset S2). Due to
the large number of affected pathways we limited our systematic
analyses to the 23 most affected pathways (q,0.10) (Table 1).
Serum lipidomics reveals drug-specific changes
In order to investigate how the high dose statin treatment affects
the plasma lipid profiles, we applied the UPLC/MS based
lipidomics analysis, leading to a total of 132 identified lipid
molecular species (data available as Supporting Information
Dataset S3). Partial Least Squares Discriminant Analysis (PLS/
DA) [17] revealed drug-specific changes in lipid profiles
(Figure 1A). The PLS/DA model details are listed as Supporting
Information Text S3 and Figure S1. The differences along the first
latent variable (LV1), were associated with expected changes in
triacylglycerols and cholesterol esters in agreement with the
hypolipidemic effect expected from both drugs (Supporting
Information Table S2). Specific differences between the simvas-
tatin and atorvastatin lipid profiles were found in the third latent
variable (LV3). Following VIP analysis, the most important lipid
species were identified for each intervention group. The list of
loadings in direction of atorvastatin-simvastatin differences (LV3)
for most important lipids in simvastatin and atorvastatin groups is
Table 1. Affected pathways in simvastatin group as revealed by Gene Set Enrichment Analysis, with the False Discovery Rate (FDR)
q-value cutoff of 0.1.
..................................................................................................................................................
NAME Source SIZE ES NES NOM p-val FDR q-val
ST_T_Cell_Signal_Transduction Signalling Transduction KE 45 0,58 1,68 0,000 0,055
soddPathway BioCarta 10 0,83 1,69 0,014 0,060
Eicosanoid_Synthesis BioCarta 15 0,79 1,66 0,000 0,071
plcPathway BioCarta 8 0,78 1,69 0,000 0,072
tubbyPathway BioCarta 7 0,70 1,70 0,000 0,076
caspasePathway BioCarta 23 0,68 1,65 0,008 0,077
CR_DEATH Brentani PNAS 2003 [31] 76 0,53 1,64 0,005 0,079
hivnefPathway BioCarta 58 0,56 1,64 0,000 0,085
ephA4Pathway BioCarta 10 0,86 1,61 0,004 0,085
deathPathway BioCarta 33 0,59 1,61 0,005 0,089
MAP00590_Prostaglandin_and_leukotriene_metabolism GenMAPP 19 0,72 1,62 0,005 0,089
nkcellsPathway BioCarta 20 0,64 1,60 0,000 0,090
SA_CASPASE_CASCADE SigmaAldrich 19 0,63 1,59 0,000 0,091
rac1Pathway BioCarta 22 0,73 1,62 0,004 0,092
ST_Dictyostelium_discoideum_cAMP_Chemotaxis_Pathway Signalling Transduction KE 33 0,64 1,61 0,007 0,093
nktPathway BioCarta 29 0,62 1,62 0,018 0,094
eosinophilsPathway BioCarta 8 0,77 1,58 0,025 0,094
tall1Pathway BioCarta 15 0,56 1,60 0,003 0,095
il17Pathway BioCarta 15 0,78 1,57 0,023 0,095
CBF_LEUKEMIA_DOWNING_AML Manually Curated 75 0,60 1,58 0,023 0,097
ureacyclePathway BioCarta 7 0,87 1,57 0,008 0,098
cell_motility GO 116 0,61 1,58 0,014 0,098
MAP00562_Inositol_phosphate_metabolism GenMAPP 20 0,65 1,57 0,032 0,099
No pathways were affected in atorvastatin or placebo groups.
doi:10.1371/journal.pone.0000097.t001
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differences between the two statins can be considered as lipid-class
specific, with specific upregulation of several phosphatidylethano-
lamines species and selective pools of long chain triacylglycerols.
Similarly, downregulation of ether phosphocholines and choles-
terol esters were observed in the simvastatin group compared to
the atorvastatin group.
Combined lipidomics and gene expression
We wanted to identify if any of the lipidomic changes in plasma
could be used as a marker of altered gene expression in muscle in
the high dose simvastatin intervention group. Therefore we
investigated if any of these gene expression changes were
associated with the differences observed in the serum lipidome.
We selected a subset of genes based on GSEA analysis.
Specifically genes from PLC, tubby, eicosanoid biosynthesis, and
sodd pathways were chosen, based on their ranking as 2nd to 5th
on FDR q-value. The top scored pathway ‘‘ST_T_Cell_Signal_-
Transduction’’ was not selected for further analysis since it is less
pathway-specific than the other four and overlaps with the PLC
pathway. The PLS/DA analysis on combined muscle gene
expression (38 transcripts) and plasma lipid profile data revealed
clear differences between the three treatment groups (Figure 2A).
The PLS/DA model details are listed as Supporting Information
Text S4. Simvastatin treatment was primarily associated with the
Figure 1. Partial least squares discriminant analysis (PLS/DA) of serum lipidomics data. Results after 8 week treatment from placebo (N=11),
atorvastatin (N=14), and simvastatin (N=12) groups, with 132 identified lipid species included in analysis as variables. For each molecular species
and each subject, its level after the 8 week treatment period was scaled by subtracting its median level across all subjects prior to treatment and
divided by corresponding standard deviation. Four latent variables were used in the model (Q
2=0.46). The labels are patient ID numbers. The lines
outlining different groups are shown as a guide. (A) The scores for Latent Variables (LV) 1 and 3 reveal serum lipid changes specific to the statin
treatment (LV1) as well as statin-specific changes (LV3). (B) Loadings on LV3 for most important lipids in simvastatin or atorvastatin groups selected
by VIP analysis. Only lipids for which at least one of the two groups has VIP value greater than 2 are shown.
doi:10.1371/journal.pone.0000097.g001
Figure 2. PLS/DA analysis on combined muscle gene expression and serum lipid data. Results after intervention for the subjects from placebo
(N=5), atorvastatin (N=6), and simvastatin (N=6) groups. Total 38 genes from four enriched pathways and 132 lipids were included in the analysis as
variables. Data was autoscaled prior to multivariate analysis. Three latent variables were used in the model (Q
2=0.50). The labels are patient ID
numbers. (A) The PLS/DA score plot reveals treatment-specific differences between the treatments are observed in molecular profiles after
intervention. (B) Loadings for the first two latent variables reveal plasma lipid classes and muscle pathways associated with specific interventions. LPC
is shorthand for lysophosphatidylcholine (for example GPCho(18:0/0:0)).
doi:10.1371/journal.pone.0000097.g002
Statin-Affected Pathways
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synthesis pathways as well as changes in multiple phosphatidyl-
ethanolamine and sphingomyelin molecular species (Figure 2B).
Since the PLS analysis maximizes the product of variance matrix
of measured variables (e.g. combined gene expression and lipid
profile data) and correlation of measured data with properties of
interest (e.g. treatment groups), our results indicate that there is
a high degree of correlation between the upregulated genes
(pathways) in skeletal muscle and specific lipids plasma changes in
the simvastatin group.
The results from combined gene expression and lipid PLS/DA
analysis raise the possibility that plasma lipid biomarkers may be
found for the pathway changes observed in the muscle. In order to
investigate this possibility, we performed regression analysis of
plasma lipid profile data on a muscle selected marker gene
expression profile. We chose arachidonate 5-lipoxygenase activat-
ing protein (ALOX5AP, Uniprot ID: P20292) as the marker for
simvastatin dysregulated pathway changes in muscle. The
ALOX5AP gene was selected based on high VIP scores in
multiple PLS/DA analyses, PCR validated significant fold change
in the simvastatin group, and its well known (pro-inflammatory)
biological role [25]. As the main goal of this analysis was discovery
of potential plasma molecular markers for statin induced muscle
toxicity, we applied a shrinkage regression method lasso [21]
aiming to find a subset of plasma lipids predictive of specific gene
expression levels in skeletal muscle. Figure 3A shows the results of
the lasso model for NZ=25 non-zero lipid variables. The variables
and their coefficients are shown in Figure 3B. The lasso analysis
was also performed for NZ=5, 10, 15, and 20 non-zero variables
(Supporting Information Tables S3–S7 and Figures S2–S5). Our
analyses identified ALOX5AP gene expression in muscle had
a high positive regression coefficients with plasma levels of
phosphatidylethanolamine (42:6) and negative for the cholesterol
ester ChoE(18:0), i.e. both type of lipids were selected as the non-
zero variables in all regression analyses, with consistent results.
Also in all analyses except NZ=5, the sphingomyelins SM(d18:1/
24:0) and SM(d18:1/24:1) showed negative regression coefficients
(Figure 2B). Also the ether phosphocholines were selected with
consistently negative coefficients, in agreement with PLS/DA
analyses (Figures 1B and 2B).
DISCUSSION
Our systems biology strategy using combined gene expression and
lipidomics analyses revealed that simvastatin at high doses induces
significant changes in the expression of multiple genes controlling
metabolic and inflammatory pathways in a non-hepatic tissue.
This observation markedly contrast with the minimum gene
expression changes observed in skeletal muscle with atorvastin
40mg. Our studies also revealed novel plasma biomarker
candidates for safety assessment of statin treatment before
recorded changes in muscle metabolism become clinically evident.
Similar to an earlier report [26], expression of genes related to
cholesterol metabolism or mevalonate pathway were only
modestly affected by statins in the present study. Thus, our data
do not directly support the view that statins would cause
mitochondrial dysfunction by reducing ubiquinone, a mitochon-
drial coenzyme with a cholesterol synthetic pathway derived side-
chain, due to inhibition of HMG-CoA reductase in the muscle.
Similarly we were not able to provide evidence that statins would
lead to inhibition of protein synthesis, signal transduction and
metabolism due to decreased muscle mevalonate acid. Since our
patients did not have any signs of clinical myopathy and muscle
damage, we were not able to judge the significance of early
proapoptotic markers during the course of the myopathy.
However, in the GSEA analysis several pro-apoptosis pathways
already appeared with significant FDR q-values at these early
stages and, therefore, the present results support the role of pro-
apoptosis pathways in statin myotoxicity. Furthermore, the
hypothesis of an increased Ca2+ influx as a mediator of statin
induced toxicity is supported by the significant up-regulation of
phospholipase C pathway and by the dysregulation of genes
encoding for calcium binding proteins (Supporting Information
Dataset S2) in the present study. Another hallmark of high dose
simvastatin effect in muscle is the activation of pro-inflammatory
pathways such as eicosanoid synthesis. However, the present
results cannot reveal the actual trigger leading to impaired
mitochondrial function and induction of these proinflamatory
pathways.
Atorvastatin and simvastatin treatments also resulted in specific
plasma lipidome profiles. Thus, lipidomics analysis may have the
potential of providing individualized specific lipid lowering agents
Figure 3. Regression of plasma lipid data on arachidonate 5-lipoxygenase activating protein (ALOX5AP) muscle gene expression profile using
the lasso method. 25 lipid variables were chosen to build the regression model. (A) ALOX5AP expression values as predicted by the model. (B)
Regression coefficients for the lipid species selected by lasso.
doi:10.1371/journal.pone.0000097.g003
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lipid biomarkers is elucidated. The role of sphingolipids as
independent predictors of coronary artery disease has been
previously suggested [27]. However, our results demonstrate that
plasma sphingomyelin changes in response to statin therapy varies
for different sphingomyelin molecular species. This raises
important questions about the biological significance of these
molecular species.
We also identified ether phospholipids as another type of lipids
differentially regulated by simvastatin. Interestingly plasmalogens,
a most abundant sub-class of ether phospholipids, have been
associated with protection against oxidative damage [28,29].
Their observed decrease (and negative correlation with the
ALOX5AP expression) following simvastatin treatment may thus
be functionally linked to increased oxidative stress and in-
flammation in muscle. Phosphatidylethanolamines were specifi-
cally dysregulated by simvastatin. The significance of this
observation remains to be elucidated but it is interesting that
a link between the Leukotriene B4 (a lipid synthesised via
ALOX5AP) and the release of arachidonate from phosphatidyl-
ethanolamine in human neutrophils has been established [30]. All
together these data indicate that in parallel with specific gene
expression changes in skeletal muscle, treatment with simvastatin
was also associated with parallel changes in plasma of lipidic
proinflamatory markers.
One limitation of the present study is the relatively small sample
size due to obvious limitations in the number of muscle specimens
obtained from patients. However, the conclusions of the results are
strengthened by the combined genomic and lipidomic analyses.
Although it may considered a potential weakness of the study, we
decided not include at this stage any patients with acute proven
myopathy. The rational for this is that analysis of gene expression
profiles in specimens obtained from patients during acute muscle
events (unpublished results) revealed hundreds of different genes
affected in the context of muscle damage, making it rather difficult
to analyze the results as directly related to the statin treatment or
establish their potential use as early markers of myopathy.
Therefore our strategy of investigating individuals with well-
defined statin-induced mitochondrial defects during a randomized
trial allowed us to identify markers with potential diagnostic and
prognostic value. In conclusion, the combined analyses of gene
expression and lipidomics profiles in asymptomatic statin treated
individuals revealed that: a) simvastatin 80 mg induces specific
gene expression and lipid changes compared to equally efficient
atorvastatin treatments and b) that our combined transcriptomic
lipidomic analysis provides bona fide sensitive biomarkers of statin
induced metabolic changes in muscle potentially useful to identify
patients at risk early enough to prevent actual muscle damage.
These biomarkers are now available for further validation in
patients with proven statin-induced myopathy.
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